Menu

Latest Pharma Insights



HLTH 2026: NuraLogix Introduces New Compact Smart Mirror To Predict Health Risks
NuraLogix debut the Anura MagicMirror Mini at HLTH 2026, a compact smart mirror that uses facial blood-flow imaging and AI to estimate vitals and health-risk indicators from a 30-second selfie. Aimed at businesses at about $4,000, it will get a roughly $1,000 consumer version at CES in January 2027.
Medtech Insight - November 17, 2026
Combination Product Group Asks FDA To Tighten Device Terms In Container Closure Draft
The Combination Products Coalition asked FDA to define key terms and loosen fixed testing language in its container closure draft for drug-device products, while the Personal Care Products Council argued against language opposing recycled plastic content.
Medtech Insight - November 17, 2026
Jefferies 2026: CEO Goldsmith Talkin’ ‘Bout A Revolution
Rasonque is off to a flyer for pancreatic cancer but company chief Mark Goldsmith has warned that stunning sales of nearly $200m in just five weeks on the market are tricky to interpret as a sign for long-term success.
Scrip - November 17, 2026
Medtronic’s Contego Deal Demonstrates Fruits Of Staged M&A Strategy
Medtech giant’s acquisition spree continues with addition of stroke prevention system into its portfolio, setting Medtronic up to compete with similar products from Boston Scientific and InspireMD.
Medtech Insight - November 17, 2026
Chinese Companies Will Be Our Biggest Rivals By 2030, Says Pfizer CEO
But the US giant believes its ongoing cost-savings and rapid uptake of AI will help it compete with China’s low-cost, high-speed R&D.
Scrip - November 17, 2026
Fresenius Kabi Enters Canada’s Crowded Denosumab Biosimilar Market With Oncology Pre-Filled Syringe
Fresenius Kabi has launched its denosumab biosimilars Bomyntra and Conexxence in Canada, saying it is the only biosimilar maker with a pre-filled syringe for oncology.
Generics Bulletin - November 17, 2026
AESGP: Greek Study Shows EU Wastewater Levy Needs Rethink
A recently published, peer-reviewed Greek study puts pharmaceuticals at about 7% of toxic load in treated wastewater. AESGP says the European Commission must now rethink how it allocates micropollutant treatment costs, and wants the deadlines postponed.
HBW Insight - November 17, 2026
Consumer Health Advisory: Unilever’s Dove Wash Claims Upheld Amid P&G Dispute
What’s happening, why it matters and what’s next in US consumer health: Unilever ad sees off challenges, McKinsey spotlights ‘wellness takeover’ and FDA issues test guidance for emerging pathogens.
HBW Insight - November 17, 2026
Pipeline Watch: Two Approvals And Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 17, 2026
Rosemont Bolsters US Ambitions By Paying $56m For Aytu BioPharma
Rosemont Pharmaceuticals has furthered its international expansion strategy by striking a deal worth $56m to acquire US specialty player Aytu BioPharma.
Generics Bulletin - November 17, 2026
Towa’s Core Business Growth Offset By Sunsho Pharmaceuticals’ Struggles
As Towa announces interim results for the six-month period ending Sept. 30, 2026, concerns continue to mount over the Japanese firm’s struggling subsidiary, Sunsho Pharmaceuticals.
Generics Bulletin - November 17, 2026
Strategic Intent: Praxis CEO On “Unlearning,” AI And Launching Two Neuroscience Drugs At Once
In this episode of Strategic Intent, Praxis CEO Marcio Souza explains how unlearning, AI fluency and patient-centered trial design shaped its turnaround as it readies two very different neuroscience drug launches.
In Vivo - November 17, 2026
Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
US Proposal Allowing NAC Use In Supplements Frames Door For More Through ‘Preclusion Clause’
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026

Jefferies 2026: CEO Goldsmith Talkin’ ‘Bout A Revolution
Rasonque is off to a flyer for pancreatic cancer but company chief Mark Goldsmith has warned that stunning sales of nearly $200m in just five weeks on the market are tricky to interpret as a sign for long-term success.
Scrip - November 17, 2026
Chinese Companies Will Be Our Biggest Rivals By 2030, Says Pfizer CEO
But the US giant believes its ongoing cost-savings and rapid uptake of AI will help it compete with China’s low-cost, high-speed R&D.
Scrip - November 17, 2026
Pipeline Watch: Two Approvals And Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 17, 2026
Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026

HLTH 2026: NuraLogix Introduces New Compact Smart Mirror To Predict Health Risks
NuraLogix debut the Anura MagicMirror Mini at HLTH 2026, a compact smart mirror that uses facial blood-flow imaging and AI to estimate vitals and health-risk indicators from a 30-second selfie. Aimed at businesses at about $4,000, it will get a roughly $1,000 consumer version at CES in January 2027.
Medtech Insight - November 17, 2026
Combination Product Group Asks FDA To Tighten Device Terms In Container Closure Draft
The Combination Products Coalition asked FDA to define key terms and loosen fixed testing language in its container closure draft for drug-device products, while the Personal Care Products Council argued against language opposing recycled plastic content.
Medtech Insight - November 17, 2026
Medtronic’s Contego Deal Demonstrates Fruits Of Staged M&A Strategy
Medtech giant’s acquisition spree continues with addition of stroke prevention system into its portfolio, setting Medtronic up to compete with similar products from Boston Scientific and InspireMD.
Medtech Insight - November 17, 2026

AESGP: Greek Study Shows EU Wastewater Levy Needs Rethink
A recently published, peer-reviewed Greek study puts pharmaceuticals at about 7% of toxic load in treated wastewater. AESGP says the European Commission must now rethink how it allocates micropollutant treatment costs, and wants the deadlines postponed.
HBW Insight - November 17, 2026
Consumer Health Advisory: Unilever’s Dove Wash Claims Upheld Amid P&G Dispute
What’s happening, why it matters and what’s next in US consumer health: Unilever ad sees off challenges, McKinsey spotlights ‘wellness takeover’ and FDA issues test guidance for emerging pathogens.
HBW Insight - November 17, 2026
US Proposal Allowing NAC Use In Supplements Frames Door For More Through ‘Preclusion Clause’
Proposed rule notes regulatory emphasis on protecting incentives for new drug development but suggests FDA could consider requests for exceptions to prohibition on using in supplements ingredients previously studied or approved for use as drugs.
HBW Insight - November 17, 2026

Fresenius Kabi Enters Canada’s Crowded Denosumab Biosimilar Market With Oncology Pre-Filled Syringe
Fresenius Kabi has launched its denosumab biosimilars Bomyntra and Conexxence in Canada, saying it is the only biosimilar maker with a pre-filled syringe for oncology.
Generics Bulletin - November 17, 2026
Rosemont Bolsters US Ambitions By Paying $56m For Aytu BioPharma
Rosemont Pharmaceuticals has furthered its international expansion strategy by striking a deal worth $56m to acquire US specialty player Aytu BioPharma.
Generics Bulletin - November 17, 2026
Towa’s Core Business Growth Offset By Sunsho Pharmaceuticals’ Struggles
As Towa announces interim results for the six-month period ending Sept. 30, 2026, concerns continue to mount over the Japanese firm’s struggling subsidiary, Sunsho Pharmaceuticals.
Generics Bulletin - November 17, 2026

Strategic Intent: Praxis CEO On “Unlearning,” AI And Launching Two Neuroscience Drugs At Once
In this episode of Strategic Intent, Praxis CEO Marcio Souza explains how unlearning, AI fluency and patient-centered trial design shaped its turnaround as it readies two very different neuroscience drug launches.
In Vivo - November 17, 2026